Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: email@example.com
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
Survey finds excess health problems in lesbians, gays, bisexuals
28 Jun 2016 at 3:47pm
By Andrew M. Seaman Gay, lesbian and bisexual individuals reported more health problems than straight men and women, in a large U.S. survey. For the first time since its launch in 1957, the National Health Interview Survey in 2013 and 2014 included a question about sexual orientation. With nearly 69,000 participants, the survey revealed that lesbian, gay and bisexual adults "were more likely to report impaired physical and mental health, heavy alcohol consumption, and heavy cigarette use, potentially due to the stressors that (they) experience as a result of interpersonal and structural discrimination," researchers wrote online June 28 in JAMA Internal Medicine.
Woman injured, gunman dead in downtown Denver shooting
28 Jun 2016 at 3:36pm
(Reuters) - A woman was critically injured in a shooting inside a downtown Denver office building on Tuesday and police said the suspected gunman was pronounced dead at the scene with what appeared to be a self-inflicted gunshot wound. Denver Police spokesman Doug Schepman told reporters at a news conference that the woman was shot multiple times around 2:45 p.m. local time and was taken to a hospital in critical condition.
Politicians, Gay Rights Groups Calls on FDA to Lift Blood Donor Ban
28 Jun 2016 at 3:00pm
Gay rights groups and members of Congress called on the U.S. Food and Drug Administration to reverse the guideline that bars gay and bisexual men from donating blood unless they abstain from sex for one year. Florida Rep. Alan Grayson, whose district includes Orlando, said not allowing many gay and bisexual men to donate blood is discriminatory during a call with reporters today, adding that the ban should be lifted to "treat all people equally." He pointed out that in times of crisis, such as the June 12 shooting at the Pulse nightclub that killed 49 people, people want to give back to the community. "We had two blocks that had to be cordoned off of people anxious to give blood that day, in the rain," Grayson said, referring to the day after the Orlando nightclub shooting.
U.S. panel backs claim Lilly diabetes drug cuts cardiac death
28 Jun 2016 at 2:58pm
Eli Lilly & Co and Boehringer Ingelheim should be allowed to claim that their diabetes drug Jardiance cuts the risk of cardiovascular death, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday. The FDA is not obliged to follow the advice of its advisory committees but typically does so. Jardiance, also known as empagliflozin, was approved in 2014 to help lower blood sugar in patients with type 2 diabetes.
Binge-eating disorder can be treated with talk therapy or drugs
28 Jun 2016 at 2:57pm
By Andrew M. Seaman People with recurring episodes of binge-eating can be helped with talk therapy or medication, according to a new review of previous studies. People with binge-eating disorder have brief, psychologically distressing binge-eating episodes multiple times a week for at least three months. The disorder is linked to mental health problems, chronic pain, obesity and diabetes, the researchers write in Annals of Internal Medicine.
Zika-Related Microcephaly Reported in Florida for First Time
28 Jun 2016 at 2:37pm
Zika-virus-related microcephaly has been reported for the first time in Florida. A woman from Haiti gave birth to a child with microcephaly in the state, the Florida Department of Health said today. There have been two other cases of women in the U.S. giving birth to children with Zika-related microcephaly.
Golf's gender divide over Rio, and Zika
28 Jun 2016 at 2:00pm
By Mark Lamport-Stokes (Reuters) - When it comes to golfers and their interest in competing at this year's Olympic Games in Rio de Janeiro, a curious gender divide is emerging which, at first glance, is counter-intuitive. While world number one Jason Day and fourth-ranked Rory McIlroy are among several big names in the men's game who have already opted out of Rio, not a single women's player has yet withdrawn from global sport's showpiece. Both Day and McIlroy have cited Zika fears as their prime reason for pulling out, saying they were unwilling to put either themselves or their families at risk from a mosquito-borne virus that can cause crippling birth defects.
Olympics-Golf's gender divide over Rio, and Zika
28 Jun 2016 at 1:55pm
By Mark Lamport-Stokes June 28 (Reuters) - When it comes to golfers and their interest in competing at this year's Olympic Games in Rio de Janeiro, a curious gender divide is emerging which, at first glance, is counter-intuitive. While world number one Jason Day and fourth-ranked Rory McIlroy are among several big names in the men's game who have already opted out of Rio, not a single women's player has yet withdrawn from global sport's showpiece. Both Day and McIlroy have cited Zika fears as their prime reason for pulling out, saying they were unwilling to put either themselves or their families at risk from a mosquito-borne virus that can cause crippling birth defects.
Doctors less satisfied, more burned out with electronic records
28 Jun 2016 at 1:31pm
By Kathryn Doyle Most doctors who use electronic health records and order entry software tend to be less satisfied with how much time they spend on clerical tasks and are at higher risk of burnout than others, according to a new study. Electronic health records ? EHR for short - are ?focused on documentation for billing as opposed to efficient and effective documentation of clinical care,? said Dr. Ann O?Malley of Mathematica Policy Research in Washington, D.C., who was not part of the new study. This makes the EHR less useful for actual patient care, which can be frustrating for doctors, she told Reuters Health by email.
Jailed Bahraini activist taken to hospital with heart problems-supporters
28 Jun 2016 at 1:27pm
Prominent Bahraini rights campaigner Nabeel Rajab, in detention for alleged remarks criticizing the kingdom's involvement in the war in Yemen and its prison system, was taken to hospital with a heart condition, supporters said on Twitter. A government official said Rajab had undergone medical checks in hospital and described his condition as normal. The 51-year-old activist, founder of the Bahrain Centre for Human Rights, had been repeatedly imprisoned since pro-democracy protests rocked the Western-allied Gulf island in 2011.
FDA approves first pill to treat all forms of hepatitis C
28 Jun 2016 at 1:19pm
WASHINGTON (AP) ? Federal health officials on Tuesday approved the first pill to treat all major forms of hepatitis C, the latest in a series of drug approvals that have reshaped treatment of the liver-destroying virus.
Sweet potato experts win World Food Prize
28 Jun 2016 at 12:48pm
By Isma'il Kushkush WASHINGTON (Reuters) - Four scientists who specialized in sweet potatoes were named the winners of this year's World Food Prize on Tuesday for their work to make foods more nutritious. Maria Andrade of Cape Verde, Robert Mwanga of Uganda and American Jan Low, who all are from the Lima, Peru-based International Potato Center, and American Howarth Bouis of the international research group HarvestPlus were honored in a ceremony at the U.S. State Department. Kenneth M. Quinn, president of the World Food Prize Foundation, called their work "a breakthrough achievement in developing and implementing biofortification." He defined biofortification as "the process of breeding critical vitamins and micronutrients into staple crops, thereby dramatically reducing hidden hunger and improving health for millions and millions of people." The honorees' work has focused on the orange-fleshed sweet potato, an important source of vitamin A, especially in sub-Saharan Africa.
Senate Democrats block GOP's Zika funding bill
28 Jun 2016 at 12:47pm
WASHINGTON (AP) ? A dysfunctional Senate split along party lines on Tuesday and left a $1.1 billion proposal to fight the Zika virus in limbo, despite growing fears and a more than 800 cases of Zika infection in the continental U.S.
Supreme Court rejects pharmacists' religious rights appeal
28 Jun 2016 at 12:08pm
OLYMPIA, Wash. (AP) ? The U.S. Supreme Court on Tuesday declined to hear an appeal from Washington state pharmacists who said they have religious objections to dispensing Plan B or other emergency contraceptives.
Gilead wins U.S. nod for drug for all types of hepatitis C
28 Jun 2016 at 11:42am
(Reuters) - U.S. health regulators on Tuesday approved a combination drug by Gilead Sciences Inc that is the first available treatment for all six major forms of hepatitis C, advancing the company's leadership in the field and sending its shares up more than 4 percent. Gilead said in a separate statement that it priced the drug at $74,760 for a 12-week regimen. Gilead has dominated the hepatitis C market over rivals AbbVie and Merck & Co with its high-priced and highly effective treatments Sovaldi and the combination drug Harvoni.